A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

NCT02925117 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

167

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Upadacitinib
DRUG: Placebo

Sponsor

AbbVie